Mutant K-Ras Activation of the Proapoptotic MST2 Pathway Is Antagonized by Wild-Type K-Ras

Agathanggelou, 2005, Role of the Ras-association domain family 1 tumor suppressor gene in human cancers, Cancer Res., 65, 3497, 10.1158/0008-5472.CAN-04-4088 Al-Mulla, 1998, Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality, J. Pathol., 185, 130, 10.1002/(SICI)1096-9896(199806)185:2<130::AID-PATH85>3.0.CO;2-M Al-Mulla, 2006, Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients, J. Clin. Oncol., 24, 5672, 10.1200/JCO.2006.07.5499 Amit, 2007, A module of negative feedback regulators defines growth factor signaling, Nat. Genet., 39, 503, 10.1038/ng1987 Avruch, 2009, Rassf family of tumor suppressor polypeptides, J. Biol. Chem., 284, 11001, 10.1074/jbc.R800073200 Aylon, 2006, A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization, Genes Dev., 20, 2687, 10.1101/gad.1447006 Barbacid, 1987, ras genes, Annu. Rev. Biochem., 56, 779, 10.1146/annurev.bi.56.070187.004023 Benlloch, 2006, Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology, J. Mol. Diagn., 8, 540, 10.2353/jmoldx.2006.060070 Bivona, 2006, PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis, Mol. Cell, 21, 481, 10.1016/j.molcel.2006.01.012 Buday, 2008, Many faces of Ras activation, Biochim. Biophys. Acta, 1786, 178 Chen, 1993, Mapping of the p53 and mdm-2 interaction domains, Mol. Cell. Biol., 13, 4107, 10.1128/MCB.13.7.4107 Cox, 2003, The dark side of Ras: regulation of apoptosis, Oncogene, 22, 8999, 10.1038/sj.onc.1207111 De Roock, 2010, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis, Lancet Oncol., 11, 753, 10.1016/S1470-2045(10)70130-3 Donninger, 2007, The RASSF1A tumor suppressor, J. Cell Sci., 120, 3163, 10.1242/jcs.010389 Downward, 2003, Targeting RAS signalling pathways in cancer therapy, Nat. Rev. Cancer, 3, 11, 10.1038/nrc969 Drosten, 2010, Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival, EMBO J., 29, 1091, 10.1038/emboj.2010.7 Gangarosa, 1997, A raf-independent epidermal growth factor receptor autocrine loop is necessary for Ras transformation of rat intestinal epithelial cells, J. Biol. Chem., 272, 18926, 10.1074/jbc.272.30.18926 Haigis, 2008, Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon, Nat. Genet., 40, 600, 10.1038/ng.115 Hamilton, 2009, ATM regulates a RASSF1A-dependent DNA damage response, Curr. Biol., 19, 2020, 10.1016/j.cub.2009.10.040 Hegymegi-Barakonyi, 2009, Tyrosine kinase inhibitors - small molecular weight compounds inhibiting EGFR, Curr. Opin. Mol. Ther., 11, 308 Holgren, 2010, Sprouty-2 controls c-Met expression and metastatic potential of colon cancer cells: sprouty/c-Met upregulation in human colonic adenocarcinomas, Oncogene, 29, 5241, 10.1038/onc.2010.264 Johnson, 2006, Putting the Oncogenic and Tumor Suppressive Activities of E2F into Context, Curr. Mol. Med., 6, 731 Johnston, 2005, Stage II colorectal cancer: to treat or not to treat, Oncologist, 10, 332, 10.1634/theoncologist.10-5-332 Karnoub, 2008, Ras oncogenes: split personalities, Nat. Rev. Mol. Cell Biol., 9, 517, 10.1038/nrm2438 Khokhlatchev, 2002, Identification of a novel Ras-regulated proapoptotic pathway, Curr. Biol., 12, 253, 10.1016/S0960-9822(02)00683-8 Kreeger, 2009, RAS mutations affect tumor necrosis factor-induced apoptosis in colon carcinoma cells via ERK-modulatory negative and positive feedback circuits along with non-ERK pathway effects, Cancer Res., 69, 8191, 10.1158/0008-5472.CAN-09-1921 Linardou, 2008, Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer, Lancet Oncol., 9, 962, 10.1016/S1470-2045(08)70206-7 Liu, 2011, KRAS gene mutation in colorectal cancer is correlated with increased proliferation and spontaneous apoptosis, Am. J. Clin. Pathol., 135, 245, 10.1309/AJCP7FO2VAXIVSTP Lu, 2010, Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver, Proc. Natl. Acad. Sci. USA, 107, 1437, 10.1073/pnas.0911427107 Malumbres, 1998, RAS pathways to cell cycle control and cell transformation, Front. Biosci., 3, d887, 10.2741/A331 Matallanas, 2003, Differences on the inhibitory specificities of H-Ras, K-Ras, and N-Ras (N17) dominant negative mutants are related to their membrane microlocalization, J. Biol. Chem., 278, 4572, 10.1074/jbc.M209807200 Matallanas, 2007, RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein, Mol. Cell, 27, 962, 10.1016/j.molcel.2007.08.008 Matallanas, 2008, A Hippo in the ointment: MST signalling beyond the fly, Cell Cycle, 7, 879, 10.4161/cc.7.7.5630 Minoo, 2007, Prognostic significance of mammalian sterile20-like kinase 1 in colorectal cancer, Mod. Pathol., 20, 331, 10.1038/modpathol.3800740 Morton, 2010, Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer, Proc. Natl. Acad. Sci. USA, 107, 246, 10.1073/pnas.0908428107 Normanno, 2009, Implications for KRAS status and EGFR-targeted therapies in metastatic CRC, Nat. Rev. Clin. Oncol., 6, 519, 10.1038/nrclinonc.2009.111 O'Connell, 2007, A more serine way to die: defining the characteristics of serine protease-mediated cell death cascades, Biochim. Biophys. Acta, 1773, 1491, 10.1016/j.bbamcr.2007.08.002 O'Neill, 2004, Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1, Science, 306, 2267, 10.1126/science.1103233 Ogino, 2005, Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer, Clin. Cancer Res., 11, 6650, 10.1158/1078-0432.CCR-05-0738 Ortiz-Vega, 2002, The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1, Oncogene, 21, 1381, 10.1038/sj.onc.1205192 Pardali, 2007, Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer, Biochim. Biophys. Acta, 1775, 21 Pollock, 2005, Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells, Cancer Res., 65, 1244, 10.1158/0008-5472.CAN-04-1911 Puyol, 2010, A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma, Cancer Cell, 18, 63, 10.1016/j.ccr.2010.05.025 Richter, 2009, The RASSF proteins in cancer; from epigenetic silencing to functional characterization, Biochim. Biophys. Acta, 1796, 114 Romano, 2010, Proapoptotic kinase MST2 coordinates signaling crosstalk between RASSF1A, Raf-1, and Akt, Cancer Res., 70, 1195, 10.1158/0008-5472.CAN-09-3147 Shaw, 2007, Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis, Genes Dev., 21, 694, 10.1101/gad.1526207 Shirasawa, 1993, Altered growth of human colon cancer cell lines disrupted at activated Ki-ras, Science, 260, 85, 10.1126/science.8465203 Siena, 2009, Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer, J. Natl. Cancer Inst., 101, 1308, 10.1093/jnci/djp280 Solca, 2004, Inhibition of epidermal growth factor receptor activity by two pyrimidopyrimidine derivatives, J. Pharmacol. Exp. Ther., 311, 502, 10.1124/jpet.104.069138 Stieglitz, 2008, Novel type of Ras effector interaction established between tumour suppressor NORE1A and Ras switch II, EMBO J., 27, 1995, 10.1038/emboj.2008.125 Takayama, 1998, Aberrant crypt foci of the colon as precursors of adenoma and cancer, N. Engl. J. Med., 339, 1277, 10.1056/NEJM199810293391803 To, 2006, A functional switch from lung cancer resistance to susceptibility at the Pas1 locus in Kras2LA2 mice, Nat. Genet., 38, 926, 10.1038/ng1836 Wade, 2010, The p53 orchestra: Mdm2 and Mdmx set the tone, Trends Cell Biol., 20, 299, 10.1016/j.tcb.2010.01.009 Watanabe, 1996, An effect of K-ras gene mutation on epidermal growth factor receptor signal transduction in PANC-1 pancreatic carcinoma cells, Int. J. Cancer, 67, 264, 10.1002/(SICI)1097-0215(19960717)67:2<264::AID-IJC18>3.0.CO;2-B Yuan, 2008, Yes-associated protein (YAP) functions as a tumor suppressor in breast, Cell Death Differ., 15, 1752, 10.1038/cdd.2008.108 Zhang, 2001, Wildtype Kras2 can inhibit lung carcinogenesis in mice, Nat. Genet., 29, 25, 10.1038/ng721 Zhou, 2009, Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene, Cancer Cell, 16, 425, 10.1016/j.ccr.2009.09.026